Who we are

Oxyrane UK Limited is a biopharmaceutical company dedicated to the development of novel and biosuperior enzyme replacement therapies (ERT) to treat lysosomal storage diseases, a class of more than 40 rare, inherited diseases. Founded in 2006, the Company is headquartered in Manchester, United Kingdom with research facilities in Ghent, Belgium.

What we do

Using a proprietary, glycoengineered yeast platform (based on the yeast Yarrowia lipolytica), Oxyrane produces human lysosomal enzymes with high levels of mannose 6-phosphate, the sugar-based targeting mechanism that enables clinically effective enzyme uptake and localisation, potentially facilitating efficacy at low product doses.

Our Research

Oxyrane is currently at pre-clinical stage with its first potential ERT treatment, targeting Pompe disease. We are currently preparing to advance our research into clinical trials.

Pompe Disease

Pompe disease (also known as glycogen storage disease type II or acid maltase deficiency) is a rare, serious lysosomal storage disease in which a defective or deficient lysosomal acid alpha-glucosidase enzyme leads to muscle and nerve cell damage. If untreated, the infantile form of Pompe disease is fatal - often before age one - due to cardiorespiratory failure.

Contact Information

UK Telephone: +44 (0) 161 227 8887        Belgium Telephone: +32 (0) 9 261 7700        Email: info@oxyrane.com